Incyte | INCY - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Acadia Pharmaceuticals USD 851.46M 31.77M 2026-03
Agenus USD 35M 32M 2026-03
Agios Pharmaceuticals USD 113.6M 24.47M 2026-03
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
Amgen USD 12.04B 2.91B 2026-03
BioCryst Pharmaceuticals USD 171.59M 164.32M 2026-03
Biogen USD 3.38B 374.2M 2026-03
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Eli Lilly USD 5.28B 1.99B 2026-03
Exelixis USD 226.15M 256.34M 2026-03
Gilead Sciences USD 7.56B 234M 2025-12
Incyte USD 4.02B 435.22M 2026-03
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
MacroGenics USD 66.52M 9.3M 2026-03
Merck USD 5.33B 9.24B 2026-03
Moderna USD 1.91B 687M 2026-03
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
Novartis USD 6.88B 4.56B 2026-03
Novartis USD 9.56B 2.9B 2025-09
Pfizer USD 1.7B 561M 2026-03
PTC Therapeutics USD 833.99M 150.66M 2026-03
Puma Biotechnology USD 53.52M 1.14M 2025-09
Regeneron Pharmaceuticals USD 2.96B 15.9B 2026-03
Sarepta Therapeutics USD 464.45M 336.83M 2026-03
Ultragenyx Pharmaceutical USD 175M 246M 2026-03
Vertex Pharmaceuticals USD 7.25B 638.6M 2026-03